Ask AI
HBV in Key Communities

CE / CME

HBV in Key Communities: Strategies to Overcome Barriers and Elevate Care

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Released: March 12, 2026

Expiration: March 11, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. World Health Organization. Hepatitis B. who.int/news-room/fact-sheets/detail/hepatitis-b. Accessed February 25, 2026.
  2. UNAIDS. Global HIV & AIDS statistics—fact sheet. unaids.org/en/resources/fact-sheet. Accessed February 25, 2026.
  3. World Health Organization. Hepatitis C. who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed February 25, 2026.
  4. Centers for Disease Control and Prevention. Hepatitis B surveillance. cdc.gov/hepatitis-surveillance-2023/hepatitis-b/index.html. Accessed February 25, 2026.
  5. Nohep.org. The race to elimination. nohep.org/the-race-to-elimination. Accessed February 25, 2026.
  6. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. afro.who.int/publications/combating-hepatitis-b-and-c-reach-elimination-2030. Accessed February 25, 2026.
  7. Lewis KC, Heslin KC, McCree DH. Health equity and viral hepatitis in the United States. Public Health Rep. 2024;[Epub ahead of print].
  8. Lim JK, Nguyen MH, Kim WR, et al. Prevalence of chronic hepatitis B virus infection in the United States. Am J Gastroenterol. 2020;115:1429-1438.
  9. Kim HS, Rotundo L, Yang JD, et al. Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States. J Viral Hepat. 2017;24:1052-1066. 
  10. Ye Q, Kam LY, Yeo YH, et al. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J Hepatol. 2022;76:63-74. 
  11. Centers for Disease Control and Prevention. Know hepatitis B. cdc.gov/knowhepatitisb/index.htm. Accessed February 25, 2026.
  12. Rossi C, Shrier I, Marshall L, et al. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS One. 2012;7:e44611.
  13. Lemoine M, Thursz MR. Battlefield against hepatitis B infection and HCC in Africa. J Hepatol. 2017;66:645-654.
  14. Garren P, Serper M. Chronic Hepatitis B in US Veterans. Curr Hepatol Rep. 2019;18:310-315.
  15. Centers for Disease Control and Prevention. Fast facts: HIV in the United States. cdc.gov/hiv/data-research/facts-stats/index.html. Accessed February 25, 2026.
  16. Centers for Disease Control and Prevention. Clinical testing guidance for HIV. cdc.gov/hivnexus/hcp/diagnosis-testing/index.html. Accessed February 25, 2026.
  17. Centers for Disease Control and Prevention. Hepatitis B basics. cdc.gov/hepatitis-b/about/index.html. Accessed February 25, 2026.
  18. AIDSVu.org. Deeper look: HIV testing. aidsvu.org/resources/deeper-look/hiv-testing/. Accessed February 25, 2026.
  19. Budak JZ. Linkage to HIV care. hiv.uw.edu/go/screening-diagnosis/linkage-care/core-concept/all. Accessed February 25, 2026.
  20. Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and testing for hepatitis B virus infection: CDC recommendations - United States, 2023. MMWR Recomm Rep. 2023;72:1-25.
  21. Hepatitis B Foundation. Understanding your test results. hepb.org/prevention-and-diagnosis/diagnosis/understanding-your-test-results/. Accessed February 25, 2026.
  22. Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364:2199-207. 
  23. Clark BT, Garcia-Tsao G, Fraenkel L. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence. 2012;6:285-95.
  24. Coffin PO, Reynolds A. Ending hepatitis C in the United States: the role of screening. Hepat Med. 2014 Jul 3;6:79-87. 
  25. McGowan CE, Monis A, Bacon BR, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013;57:1325-1332. 
  26. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005;20:754-758.
  27. Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother. 2010;65:1327-1329.
  28. Fusfeld L, Aggarwal J, Dougher C, et al. Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection. BMC Infect Dis. 2013;13:234.
  29. Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci. 2007;52:1168-1176.
  30. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010;51:729-733. 
  31. Reilley B, Leston J, Redd JT, et al. Lack of access to treatment as a barrier to HCV screening: a facility-based assessment in the Indian health service. J Public Health Manag Pract. 2014;20:420-423.
  32. Hwang JP, Lok AS. USPSTF 2020 Hepatitis B screening recommendation: evidence to broaden screening and strengthen linkage to care. JAMA. 2020;324:2380-2382. 
  33. Lapointe-Shaw L, Chung H, Holder L, et al. Diagnosis of chronic hepatitis B pericomplication: risk factors and trends over time. Hepatology. 2021;73:2141-2154. 
  34. Kardashian A, Serper M, Terrault N, et al. Health disparities in chronic liver disease. Hepatology. 2023;77:1382-1403.
  35. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599.
  36. World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. who.int/publications/i/item/9789240090903. Accessed February 26, 2026.
  37. Nam JY, Chang Y, Cho H, et al. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B. J Viral Hepat. 2018;25:552-560. 
  38. Ghany MG, Pan CQ, Lok AS, et al. AASLD/IDSA practice guideline on treatment of chronic hepatitis B. Hepatology. 2025;[Epub ahead of print].
  39. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83:502-583. 
  40. World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection (text extract): executive summary. Infect Dis Immun. 2024;4:103-105.
  41. Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-1965.
  42. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12:568-574.
  43. Yang JD, Kamath PS. Revised REACH-B model for hepatocellular carcinoma risk prediction in patients with chronic hepatitis B. Ann Intern Med. 2024;177:1435-1436. 
  44. American Association for the Study of Liver Diseases. HBV figures and tables.  aasld.app.box.com/s/ehlpzy73bf22ughw6r0vri1eojpqmkkj. Accessed February 25, 2026.
  45. Vachon A, Osiowy C. Novel biomarkers of hepatitis B virus and their use in chronic hepatitis B patient management. Viruses. 2021;13:951.
  46. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139:483-490.
  47. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol. 2011;55:1121-1131. 
  48. Brouwer WP, Chan HL, Brunetto MR, et al. Repeated measurements of hepatitis B surface antigen identify carriers of inactive HBV during long-term follow-up. Clin Gastroenterol Hepatol. 2016;14:1481-1489.e5.
  49. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140-1149.e3;quiz e13-4.
  50. Liu B, Wen X, Huang C, et al. Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years. Int J Biochem Cell Biol. 2013;45:1987-1996.
  51. Howell J, Seaman C, Wallace J, et al. Pathway to global elimination of hepatitis B: HBV cure is just the first step. Hepatology. 2023;78:976-990. 
  52. Zheng J, Wang Z, Huang L, et al. Achieving chronic hepatitis B functional cure: Factors and potential mechanisms. Virus Res. 2025;351:199507.
  53. Tan YC, Lee GH, Huang DQ, et al. Future anti-HDV treatment strategies, including those aimed at HBV functional cure. Liver Int. 2023;43:1157-1169.
  54. Toumi M, Wallace J, Cohen C, et al. Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States. BMC Public Health. 2024;24:611.
  55. Slaets L, Ridder F, Lenz O, et al. Systematic review with meta-analysis: hepatitis B surface antigen decline and seroclearance in chronic hepatitis B patients on nucleos(t)ide analogues or pegylated interferon therapy. GastroHep. 2020;2:106
  56. Mak LY, Hui RW, Fung J, et al. Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress. Expert Opin Investig Drugs. 2023;32:971-983.
  57. Valliant. Bepirovirsen/GSK3389404: Antisense or TLR9 agonists? J Hepatol. 2023;78:e107.
  58. GSK. GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B. gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-b-well-1-and-b-well-2-phase-iii-trials-for-bepirovirsen-a-potential-first-in-class-treatment-for-chronic-hepatitis-b. Accessed February 25, 2026.
  59. Rogg L. Proof-of-concept trial of VH4524184 (VH-184), a third-generation integrase strand transfer inhibitor. Presented at the 2025 Conference on Retroviruses and Opportunistic Infections. March 9-12, 2025. Abstr 152.
  60. Rogg L. Presented at AIDS 2024. July 22-26, 2024. Abstr OAB2603.
  61. Grisel. Presented at the 2025 Conference on Retroviruses and Opportunistic Infections. March 9-12, 2025. Abstr 153.
  62. US Department of Health and Human Services. Viral hepatitis. National strategic plan: a roadmap to elimination for the United States 2021-2025. hhs.gov/sites/default/files/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf. Accessed February 25, 2026.
  63. Hepatitis B Foundation. hepb.org/. Accessed February25, 2026.